Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.09, read 2026-10-23
Ethical does not pass the values gate
Price2.67 USD
Fair value7.84
Ethical score70.0/100
Our investment reviews on this name
2026-09-09Read Markdown6.69-60.1% to today ✓Distribution gives way to Markdown after a 7% slide in 5 weeks
2026-08-08Read Distribution7.21-63.0% to today ✓Markup gives way to Distribution after a 19% slide in 5 weeks
2026-07-02Read Markup8.88-69.9% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
PureCycle Technologies, Inc. holds its Markdown at $2.67. The statistical read favours the sellers, held for 50 days.
As held on the ledger · 2026-10-26
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 50 days
Price at the screen
$2.67
Valuation
N/A trailing · -6.27 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.58
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
45.43%
Below 33%
Interest-bearing debt is 45.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
1.48%
Below 33%
Cash held in interest-bearing accounts and securities is 1.5% of assets, under the one-third limit.
Pass
Receivables
17.20%
Below 49%
Money owed to the company is 17.2% of assets, under the 49% limit.
Pass
Revenue purity
70.14%
Below 5%
70.1% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
PureCycle Technologies,'s business is in a permissible area, but its interest-bearing debt is about 45% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PCT's ethical verdict changes
Today PCT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-26 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 5 covering, consensus None. The average target sits +275% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Recycled plastic venture that fails to convince
Picture a plant turning old packaging back into food-grade resin that big brands could use again. PureCycle holds the licence for that process, yet it still posts zero profit margins and an 81 percent negative return on equity despite 161 percent revenue growth. The market prices the shares at a negative 7.6 times forward earnings, but the business has yet to prove it can turn those sales into cash.
We pass for straightforward reasons. The opportunity rating sits at none, the moat remains unknown and six analysts offer no consensus. A 90 percent gap to our fair value of 11.50 looks attractive only if the firm can scale without burning more capital or suffering dilution.
High execution risk sits with unproven commercial output and the usual cyclical swings in industrial demand. Currency and input-cost swings add further uncertainty in a sector that rewards proven throughput over promise. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PCT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-25Markdown$3.22+0.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it buy, with a mean price target of $12.
2026-10-18Markdown$3.22-43.2%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 43.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it buy, with a mean price target of $12.
2026-10-02Markdown$5.67-15.2%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it buy, with a mean price target of $12.
2026-09-09Markdown · changed$6.69-7.2%Entry 5
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 7.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it buy, with a mean price target of $12.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 18.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it buy, with a mean price target of $12.
2026-07-18Markup$8.88+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it buy, with a mean price target of $12.
2026-07-03Markup$8.88+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$8.88Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
